Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.79 |
| ▸ | PPARG | P37231 | 1/20 | 0.75 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | LTK | P29376 | 1/20 | 0.45 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | CCR4 | P51679 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1584735 | 1.00 | FFAR1 (0.79) | FFAR1PPARGNR4A2S1PR1LTK | |
| SCHEMBL12708157 | 0.90 | FFAR1 (0.65) | FFAR1PPARGNR4A2S1PR1LTK | |
| SCHEMBL1584664 | 0.89 | FFAR1 (0.64) | FFAR1PPARGNR4A2S1PR1LTK | |
| SCHEMBL1584667 | 0.89 | FFAR1 (0.64) | FFAR1PPARGNR4A2S1PR1LTK | |
| SCHEMBL1584485 | 0.86 | FFAR1 (1.00) | FFAR1PPARGNR4A2S1PR1LTK | |
| SCHEMBL1604202 | 0.86 | FFAR1 (1.00) | FFAR1PPARGNR4A2S1PR1LTK | |
| SCHEMBL15789668 | 0.82 | FFAR1 (0.57) | FFAR1PPARGNR4A2S1PR1LTK | |
| SCHEMBL15789670 | 0.82 | FFAR1 (0.57) | FFAR1PPARGNR4A2S1PR1LTK | |
| SCHEMBL12708019 | 0.77 | FFAR1 (0.83) | FFAR1PPARGNR4A2S1PR1LTK | |
| SCHEMBL1584330 | 0.73 | FFAR1 (0.66) | FFAR1PPARGNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486005-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| EP-2486005-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8288404-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2486005-A1 | PYRROLIDINE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044073-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR27 | FFAR1 37/4885PPARG 69/4885NR4A2 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.